Peptide Research

CagriSema: Two Molecules in One Injection

CagriSema is not a new molecule but a fixed combination of two — an amylin analogue and a GLP-1 agonist, aimed at two separate satiety pathways.

Peptide Library Editorial · June 23, 2026 · Updated August 30, 2026 · 3 min read

CagriSema: Two Molecules in One Injection — Peptide Library research guide

CagriSema is two separate molecules delivered together: cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 receptor agonist. It is a fixed-dose combination rather than a new compound.

That distinguishes it from the multi-agonist approach. Tirzepatide and retatrutide are single molecules hitting several receptors; CagriSema is two molecules each hitting their own.

Investigational. CagriSema has no approved indication and no established dose. Everything here is trial-stage information reported for reference, and nothing is dosing guidance.

Two different satiety systems

Amylin is a hormone co-secreted with insulin by pancreatic beta cells. It slows gastric emptying and promotes satiety through pathways in the hindbrain — related to, but distinct from, how GLP-1 acts.

Component

Class

Acts through

Cagrilintide

Long-acting amylin analogue

Amylin/calcitonin receptor pathways

Semaglutide

GLP-1 receptor agonist

GLP-1 receptor signalling

The rationale is that two satiety mechanisms acting together produce more effect than either alone — the same combination logic behind the multi-agonists, arrived at by a different route.

Combination versus multi-agonist

This is the genuinely interesting design question, and both approaches have real trade-offs.

  • A single multi-agonist molecule means one pharmacokinetic profile and one manufacturing process, but the receptor ratio is fixed at whatever the molecule does.

  • A fixed combination allows each component to be dosed and titrated on its own scale, at the cost of two molecules with two profiles in one injection.

It is the same trade-off that appears in far simpler form with the GLOW and KLOW blends: combining components fixes their ratio unless the format lets you vary them independently.

Where the evidence stands

CagriSema has progressed through a phase 3 programme for obesity, and systematic review and meta-analysis of the randomised evidence has been published. It has drawn particular attention because results were weighed against expectations set by tirzepatide.

Watch for cross-trial comparison when reading about it. Comparing a CagriSema result against a tirzepatide result from a different trial, population, and duration is not a like-for-like comparison, however tempting the headline arithmetic. The tirzepatide vs semaglutide guide shows how much a genuine head-to-head can shift the picture.

The vial math

Research-grade material sold under this name is typically a blend, which raises the labelling problem common to all blends: is a stated milligram figure the total, or the amount of each component?

Vial (each component)

BAC water

Concentration each

0.5 mg

1 mg

5 mg + 5 mg

2 mL

2.5 mg/mL

20 units

40 units

5 mg + 5 mg

3 mL

1.67 mg/mL

30 units

60 units

10 mg + 10 mg

4 mL

2.5 mg/mL

20 units

40 units

Resolve the per-component masses before adding water. The BPC-157 and TB-500 guide works through why that ambiguity ruins the arithmetic, and the peptide calculator supports per-component concentrations.

Storage

Storage is the same as any reconstituted vial: 2–8 °C, protected from light, never frozen, and bounded by the shorter of peptide stability and the 28-day limit on bacteriostatic water. The bacteriostatic water guide covers the detail.

Frequently asked questions

Is CagriSema a single molecule?

No. It is a fixed combination of cagrilintide and semaglutide, unlike tirzepatide which is one molecule with two receptor targets.

What is amylin?

A hormone co-secreted with insulin that slows gastric emptying and promotes satiety. Cagrilintide is a long-acting synthetic analogue of it.

Is it approved?

No. It remains investigational.

Research and educational use only. Peptide Library is an independent research and comparison platform and does not sell peptides. Nothing here is medical advice, dosing guidance, or a recommendation to administer any substance to a person or an animal. Consult a licensed clinician for anything concerning human health.

Sources

  1. 1. Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials — Naunyn-Schmiedeberg's Archives of Pharmacology (2026) Source PubMed

Author

Peptide Library Editorial

Editorial content from Peptide Library. Research and educational use only. Not medical advice.

Research smarter with Peptide Library.

Compare peptides, review vendor data, and use research calculators in one place.

Explore the Library

Research and educational use only. Not medical advice. Peptide Library does not sell peptides.